CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totaling 2,193 shares, a drop of 82.6% from the August 15th total of 12,595 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average trading volume of 10,393 shares, the days-to-cover ratio is currently 0.2 days.
CNS Pharmaceuticals Stock Performance
Shares of NASDAQ:CNSP traded down $0.02 during trading on Friday, hitting $5.73. 3,338 shares of the stock were exchanged, compared to its average volume of 529,154. CNS Pharmaceuticals has a 1-year low of $1.90 and a 1-year high of $10.59. The company has a market capitalization of $8.37 million, a price-to-earnings ratio of -0.24 and a beta of 3.06. The company’s fifty day simple moving average is $5.43 and its 200-day simple moving average is $4.35.
CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.14).
Analyst Ratings Changes
Read Our Latest Stock Report on CNSP
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of CNSP. Boothbay Fund Management LLC bought a new position in shares of CNS Pharmaceuticals during the fourth quarter worth $71,000. Stonepine Capital Management LLC acquired a new position in CNS Pharmaceuticals in the second quarter valued at about $198,719. Ikarian Capital LLC bought a new stake in shares of CNS Pharmaceuticals in the fourth quarter worth about $241,000. ADAR1 Capital Management LLC acquired a new stake in shares of CNS Pharmaceuticals during the second quarter worth about $335,000. Finally, Armistice Capital LLC bought a new position in shares of CNS Pharmaceuticals during the 2nd quarter valued at about $335,000. 14.02% of the stock is currently owned by institutional investors.
CNS Pharmaceuticals Company Profile
CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.
Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.
Featured Stories
- Five stocks we like better than CNS Pharmaceuticals
- Amgen Drops 10% on a Trial It Didn’t Even Run
- Oracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in Earnings
- TSMC Revenue Jumps 53% in August, Signaling Strong AI Chip Demand
- This AI ETF Is Missing the Biggest AI Winners
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
